Novogene Co., Ltd. (SHA:688315)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Life Science Basic Research Service	717.48M			655.75M		678.18M	552.25M	356.63M
Life Science Basic Research Service Growth	-			-		22.80%	54.85%	43.84%
Medical Research and Technical Services	275.65M			273.10M		306.22M	272.44M	234.89M
Medical Research and Technical Services Growth	-			-		12.40%	15.99%	72.97%
Sequencing Platform Services	1.06B			704.33M		384.89M	203.76M	141.74M
Sequencing Platform Services Growth	-			-		88.89%	43.76%	89.61%
Others	55.36M			230.49M		165.53M	24.22M	5.95M
Others Growth	-			-		583.39%	306.81%	-
Total	2.10B			1.86B		1.53B	1.05B	739.21M
Total Growth	-			-		45.80%	42.41%	61.23%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Hong Kong, Macau, Taiwan and Overseas	1.04B			665.79M		-	-	-
Mainland China	1.06B			1.20B		1.06B	738.25M	577.01M
Mainland China Growth	-			-		44.21%	27.94%	-
America	-			-		216.94M	120.91M	67.85M
America Growth	-			-		79.43%	78.20%	-
Europe	-			-		96.66M	76.71M	14.59M
Europe Growth	-			-		26.01%	425.83%	-
Singapore	-			-		53.52M	49.31M	21.22M
Singapore Growth	-			-		8.54%	132.40%	-
Asia-Pacific (Except Singapore and China)	-			-		103.09M	67.50M	58.54M
Asia-Pacific (Except Singapore and China) Growth	-			-		52.72%	15.31%	-
Total	2.10B			1.86B		1.53B	1.05B	739.21M
Total Growth	-			-		45.80%	42.41%	61.23%

Source: S&P Global Market Intelligence.